-
Je něco špatně v tomto záznamu ?
Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates
Kraft O, Kaspárek R, Ullmann V, Melichar F, Kropácek M, Mirzajevova M
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky
NLK
ProQuest Central
od 2000-04-01 do 2018-12-31
Health & Medicine (ProQuest)
od 2000-04-01 do 2018-12-31
Public Health Database (ProQuest)
od 2000-04-01 do 2018-12-31
- MeSH
- časové faktory MeSH
- dospělí MeSH
- holmium škodlivé účinky terapeutické užití MeSH
- koleno patologie účinky záření MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- synovitida patologie radioterapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- klinické zkoušky MeSH
The aim of this study was to evaluate adverse and therapeutic effects of applicated holmium-boro-macroaggregates (HBMAs) in the radiosynoviorthesis (RSO) of knees in patients suffering from chronic synovitis. We started RSO of the knees by means of a new radiopharmaceutical (RF) HBMA in patients with gonarthrosis, rheumatoid arthritis, chronic synovitis, psoriatic arthritis, and gout arthropathy. Seventeen (17) intra-articular injections were performed in 15 patients who were receiving a mean activity of 972 MBq (range, 904-1057) of 166Ho-HBMA. Patient inclusion to the study followed a series of inclusion and exclusion criterions. The patients were hospitalized for 3 days. Side-effects were evaluated during their hospital stay and again after 6-8 weeks. Static scintigraphy of knee joints and measurements of blood radioactivity were performed. Therapeutic effects were evaluated after 6-8 weeks and at 6 months. In 2 hours and 2 days following the application, we proved, by means of knee and inguinal scintigraphy, only insignificant radiopharmaceutical leakage from the joint cavity to the inguinal lymph nodes in 4 patients. In the treated patients, no serious adverse effects occurred. Nine (9) patients were without complaints, 4 patients had slight knee exudation, and 2 patients had great exudation. Therapeutic effects were as follows: 2 patients were without pain, 9 were with lower pain, 3 were with the same pain, and 1 patient was with increased pain. Joint motion was improved in 7 patients, remained the same in 7 patients, and was impaired in 1 patient. Analgesics consumption was lower in 5 patients, the same in 9 patients, and greater in 1 patient. Knee exudation was absent in 2 patients, lower in 4 patients, the same in 6 patients, and greater in 3 patients. In 3 patients it was necessary to do surgical RSO. This RF can extend the range of clinically used radiopharmaceuticals for RSO and to supplement space between 90Y with high energy and 186Re with 169Er with lower beta energy. The energy of 166Ho is suitable for great and medium joints (i.e., knees, hips, shoulders, elbows, wrists, and ankles).
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10001006
- 003
- CZ-PrNML
- 005
- 20111210154843.0
- 008
- 100117s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kraft, Otakar, $d 1953- $7 xx0083594
- 245 10
- $a Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates / $c Kraft O, Kaspárek R, Ullmann V, Melichar F, Kropácek M, Mirzajevova M
- 314 __
- $a Department of Nuclear Medicine, University Hospital, Ostrava-Poruba, Czech Republic. otakar.kraft@fnspo.cz
- 520 9_
- $a The aim of this study was to evaluate adverse and therapeutic effects of applicated holmium-boro-macroaggregates (HBMAs) in the radiosynoviorthesis (RSO) of knees in patients suffering from chronic synovitis. We started RSO of the knees by means of a new radiopharmaceutical (RF) HBMA in patients with gonarthrosis, rheumatoid arthritis, chronic synovitis, psoriatic arthritis, and gout arthropathy. Seventeen (17) intra-articular injections were performed in 15 patients who were receiving a mean activity of 972 MBq (range, 904-1057) of 166Ho-HBMA. Patient inclusion to the study followed a series of inclusion and exclusion criterions. The patients were hospitalized for 3 days. Side-effects were evaluated during their hospital stay and again after 6-8 weeks. Static scintigraphy of knee joints and measurements of blood radioactivity were performed. Therapeutic effects were evaluated after 6-8 weeks and at 6 months. In 2 hours and 2 days following the application, we proved, by means of knee and inguinal scintigraphy, only insignificant radiopharmaceutical leakage from the joint cavity to the inguinal lymph nodes in 4 patients. In the treated patients, no serious adverse effects occurred. Nine (9) patients were without complaints, 4 patients had slight knee exudation, and 2 patients had great exudation. Therapeutic effects were as follows: 2 patients were without pain, 9 were with lower pain, 3 were with the same pain, and 1 patient was with increased pain. Joint motion was improved in 7 patients, remained the same in 7 patients, and was impaired in 1 patient. Analgesics consumption was lower in 5 patients, the same in 9 patients, and greater in 1 patient. Knee exudation was absent in 2 patients, lower in 4 patients, the same in 6 patients, and greater in 3 patients. In 3 patients it was necessary to do surgical RSO. This RF can extend the range of clinically used radiopharmaceuticals for RSO and to supplement space between 90Y with high energy and 186Re with 169Er with lower beta energy. The energy of 166Ho is suitable for great and medium joints (i.e., knees, hips, shoulders, elbows, wrists, and ankles).
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a holmium $x škodlivé účinky $x terapeutické užití $7 D006695
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a koleno $x patologie $x účinky záření $7 D007717
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a synovitida $x patologie $x radioterapie $7 D013585
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a klinické zkoušky $7 D016430
- 700 1_
- $a Kašpárek, Richard $7 xx0100981
- 700 1_
- $a Ullmann, Vojtěch, $d 1949- $7 jk01140714
- 700 1_
- $a Melichar, František $7 xx0053036
- 700 1_
- $a Kropáček, Martin $7 xx0166212
- 700 1_
- $a Mirzajevová, Marcela $7 xx0166211
- 773 0_
- $w MED00008725 $t Cancer biotherapy & radiopharmaceuticals $g Roč. 22, č. 2 (2007), s. 296-302 $x 1084-9785
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20100114083259 $b ABA008
- 991 __
- $a 20100215142952 $b ABA008
- 999 __
- $a ok $b bmc $g 703734 $s 566176
- BAS __
- $a 3
- BMC __
- $a 2007 $b 22 $c 2 $d 296-302 $i 1084-9785 $m Cancer biotherapy & radiopharmaceuticals $x MED00008725
- LZP __
- $a 2010-b1/vtme